FDMT. – 4D Molecular Therapeutics Inc
4D Molecular Therapeutics, Inc.FDMT
$3.84Name : 4D Molecular Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $177,886,464.00
EPSttm : -3.18
4D Molecular Therapeutics, Inc.
$3.84
5.65%$0.23Float Short %
10.04
Margin Of Safety %
Put/Call OI Ratio
0.12
EPS Next Q Diff
-0.08
EPS Last/This Y
-0.58
EPS This/Next Y
-0.32
Price
3.85
Target Price
29.56
Analyst Recom
1.82
Performance Q
7.87
Relative Volume
2.52
Beta
2.84
Ticker: FDMT
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-06-02 | FDMT | 3.74 | 0.17 | 0.00 | 4211 |
| 2025-06-03 | FDMT | 3.87 | 0.17 | 0.00 | 4211 |
| 2025-06-04 | FDMT | 3.83 | 0.17 | 0.00 | 4239 |
| 2025-06-05 | FDMT | 3.9 | 0.17 | 0.00 | 4268 |
| 2025-06-06 | FDMT | 4.34 | 0.17 | 0.03 | 4290 |
| 2025-06-09 | FDMT | 4.78 | 0.18 | 0.00 | 4141 |
| 2025-06-10 | FDMT | 4.48 | 0.18 | 0.01 | 4137 |
| 2025-06-11 | FDMT | 4.37 | 0.18 | 0.25 | 4131 |
| 2025-06-12 | FDMT | 4.51 | 0.18 | 0.07 | 4182 |
| 2025-06-13 | FDMT | 4.4 | 0.18 | 0.00 | 4249 |
| 2025-06-16 | FDMT | 4.36 | 0.19 | 0.00 | 4149 |
| 2025-06-17 | FDMT | 4.16 | 0.19 | 0.00 | 4149 |
| 2025-06-18 | FDMT | 4.07 | 0.19 | 0.00 | 4147 |
| 2025-06-20 | FDMT | 4.14 | 0.19 | 0.00 | 4149 |
| 2025-06-23 | FDMT | 3.77 | 0.13 | 0.00 | 3785 |
| 2025-06-24 | FDMT | 4 | 0.13 | 0.00 | 3786 |
| 2025-06-25 | FDMT | 4.1 | 0.12 | 0.00 | 3881 |
| 2025-06-26 | FDMT | 4.07 | 0.12 | 0.06 | 3981 |
| 2025-06-27 | FDMT | 3.85 | 0.12 | 999.99 | 4299 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-06-02 | FDMT | 3.73 | -10.0 | - | -3.56 |
| 2025-06-03 | FDMT | 3.87 | -10.0 | - | -3.56 |
| 2025-06-04 | FDMT | 3.84 | -10.0 | - | -3.56 |
| 2025-06-05 | FDMT | 3.91 | -10.0 | - | -3.56 |
| 2025-06-06 | FDMT | 4.35 | -10.0 | - | -3.56 |
| 2025-06-09 | FDMT | 4.79 | -9.9 | - | -3.56 |
| 2025-06-10 | FDMT | 4.47 | -9.9 | - | -3.56 |
| 2025-06-11 | FDMT | 4.36 | -9.9 | - | -3.56 |
| 2025-06-12 | FDMT | 4.50 | -9.9 | - | -3.56 |
| 2025-06-13 | FDMT | 4.41 | -9.9 | - | -3.56 |
| 2025-06-16 | FDMT | 4.36 | -9.9 | - | -3.56 |
| 2025-06-17 | FDMT | 4.14 | -9.9 | - | -3.56 |
| 2025-06-18 | FDMT | 4.09 | -9.9 | - | -3.56 |
| 2025-06-20 | FDMT | 4.13 | -9.9 | - | -3.56 |
| 2025-06-23 | FDMT | 3.76 | -9.9 | - | -3.56 |
| 2025-06-24 | FDMT | 4.01 | -9.9 | - | -3.56 |
| 2025-06-25 | FDMT | 4.10 | -9.9 | - | -3.56 |
| 2025-06-26 | FDMT | 4.06 | -9.9 | - | -3.56 |
| 2025-06-27 | FDMT | 3.85 | -9.9 | - | -3.56 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-06-02 | FDMT | 0.00 | -8.58 | 11.24 |
| 2025-06-03 | FDMT | 0.00 | -8.58 | 11.24 |
| 2025-06-04 | FDMT | 0.00 | -8.58 | 11.24 |
| 2025-06-05 | FDMT | 0.00 | -8.58 | 11.24 |
| 2025-06-06 | FDMT | 0.00 | -8.58 | 11.24 |
| 2025-06-09 | FDMT | 0.00 | -8.54 | 11.24 |
| 2025-06-11 | FDMT | 0.00 | -8.54 | 10.48 |
| 2025-06-12 | FDMT | 0.00 | -8.54 | 10.48 |
| 2025-06-13 | FDMT | 0.00 | -8.54 | 10.48 |
| 2025-06-16 | FDMT | 0.00 | -8.50 | 10.48 |
| 2025-06-17 | FDMT | 0.00 | -8.50 | 10.48 |
| 2025-06-18 | FDMT | 0.00 | -8.50 | 10.48 |
| 2025-06-19 | FDMT | 0.00 | -8.50 | 10.48 |
| 2025-06-20 | FDMT | 0.00 | -8.50 | 10.48 |
| 2025-06-24 | FDMT | 0.00 | -8.50 | 10.48 |
| 2025-06-25 | FDMT | 0.00 | -8.50 | 10.48 |
| 2025-06-26 | FDMT | 0.00 | -8.50 | 10.04 |
| 2025-06-27 | FDMT | 0.00 | -8.50 | 10.04 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.86
Avg. EPS Est. Current Quarter
-0.69
Avg. EPS Est. Next Quarter
-0.94
Insider Transactions
Institutional Transactions
-8.5
Beta
2.84
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
20
Growth Score
31
Sentiment Score
29
Actual DrawDown %
93
Max Drawdown 5-Year %
Target Price
29.56
P/E
Forward P/E
PEG
P/S
8894.27
P/B
0.38
P/Free Cash Flow
EPS
-3.37
Average EPS Est. Cur. Y
-3.56
EPS Next Y. (Est.)
-3.88
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-767126.09
Relative Volume
2.52
Return on Equity vs Sector %
-61.5
Return on Equity vs Industry %
-43.6
EPS 1 7Days Diff
EPS 1 30Days Diff
0.01
EBIT Estimation
4D Molecular Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 227
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in Emeryville, California.
stock quote shares FDMT. – 4D Molecular Therapeutics Inc Stock Price stock today
news today FDMT. – 4D Molecular Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch FDMT. – 4D Molecular Therapeutics Inc yahoo finance google finance
stock history FDMT. – 4D Molecular Therapeutics Inc invest stock market
stock prices FDMT premarket after hours
ticker FDMT fair value insiders trading